MBody AI Ltd.MBAI
Price (close)
$4.51
Market cap
$69.0M
P/E
16.7x
Revenue (FY)
—
Net income
$4.1M
Dividend yield
—
1-year total return
-71.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What MBody AI Ltd. does.
diagnostics company aiming to redefine CRC screening through the introduction of C-Scan®, a screening test designed to detect polyps
screening technology aims to increase screening adherence worldwide and enable people to stay healthy. The system utilizes ultra-low-dose
X- rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities. CRC is the third most commonly
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$13.8M | -$17.2M | -$19.1M | -$17.6M | -$25.1M | $4.1M |
| Free cash flow | -$13.5M | -$17.3M | -$19.2M | -$17.0M | — | — |
More on MBAI.
- MBody AI Ltd. summary
- MBody AI Ltd. financial statements
- MBody AI Ltd. key metrics
- MBody AI Ltd. health scores and style box
- MBody AI Ltd. earnings
- MBody AI Ltd. dividends
- MBody AI Ltd. valuation
- MBody AI Ltd. ownership and insiders
- MBody AI Ltd. peers
Figures from MBody AI Ltd.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.